Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Nov 11;5:575. doi: 10.3389/fimmu.2014.00575

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 Poggi and Zocchi.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Scheme of possible combinations of activating and inhibiting stimuli aimed to potentiate γδT-cell anti-cancer response. 1. TLR agonists (imiquimod or resiquimod). 2. mAbs blocking PD-1, PDL-1, and CTLA-4. 3. mAbs directed to the B30.2 basic domain of BTN3A1. 4. N-BPs not only as γδ T-cell stimulating agents but as immunomodulating drugs (decrease TGF-β and increase IL-15 production by LN-MSC). 5. ADAMs specific and non-toxic inhibitors. 6. Humanized mAbs directed against tumor antigens (rituximab, trastuzumab). TC, tumor cell; EM, effector memory; MSC, mesenchymal stromal cells; ADCC, antibody-dependent cellular cytotoxicity.